In the OCTANE real-world analysis presented at EASD 2026, adults who switched from injectable semaglutide or tirzepatide to once-daily oral semaglutide lost an average of 4.1% of body weight after 3 months.
|Articles|November 1, 2014
- BioPharm International-11-01-2014
- Volume 27
- Issue 11
Cell Culture Consumables Prevent Contamination
Eppendorf's Cell Culture Consumables have an ISO class/GMP class C clean room production standard.
Advertisement
Eppendorf’s Cell Culture Consumables have an ISO class/GMP class C clean room production standard and a sterility assurance level of 10-6.
The flasks feature air filter technology, with improved ergonomic design to increase handling efficiency. Each flask is given a 100% in-line pressure test for leaks. The resealable-top dishes include a corrugated ring to improve handling and transportation, with a SplashProtect ring inside the dish to protect against cross-contamination. The plates have been designed to minimize the “edge effect” with a chimney-well design in the outer moat of the 96-well plate.
Eppendorf
Articles in this issue
almost 12 years ago
Germany Post AMNOG: Insights for BioPharmaalmost 12 years ago
Standardizing Practices for Cellular Therapy Manufacturingalmost 12 years ago
Setting Standards for Biotech Therapeutics in Indiaalmost 12 years ago
Viral Clearance Challenges in Bioprocessingalmost 12 years ago
Outside Looking Inalmost 12 years ago
Hype vs. Healthalmost 12 years ago
New Era for Generic Drugsalmost 12 years ago
DoE Provides Benefits, but Preparation Is Necessaryalmost 12 years ago
Vector Manufacturing and Testing for Gene and Cell Therapy ApplicationsAdvertisement
Related to this article
Denosumab-adet now covers all 3 Xgeva indications, widening lower-cost treatment access for cancer patients with bone complications.
More than half of patients achieved clear or almost clear hands and feet with lebrikizumab by week 16, and 77% reported satisfaction with clearance.
Sponsored
Meeta Gulyani, Ecolab Life Sciences, shares where biomanufacturing is headed next and why the relationship between drug developers and their suppliers is changing along with it.
Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.
Novo gains global rights, excluding Greater China, to HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist that Hengrui says has potential for once-weekly oral dosing in obesity and type 2 diabetes.
NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.
Updated 36-month data in 15 high-dose patients showed 80% slowing on cUHDRS, while the 48-month cUHDRS result did not reach statistical significance. uniQure attributes the gap to attrition in the external control, and the FDA is reviewing a BLA based on the 36-month data.
Advertisement
Advertisement